Dinaciclib (SCH727965)

Catalog No.S2768 Synonyms: PS-095760

Dinaciclib (SCH727965) Chemical Structure

Molecular Weight(MW): 396.49

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 470 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • CDK4/6 inhibition has potent cytostatic effect in HER2-positive models. The indicated cells were treated with PD-0332991 (1 uM) or Dinaciclib (1 uM) for 96 hours and plates were stained with crystal violet.

    Genes Cancer 2014 5(7-8), 261-72. Dinaciclib (SCH727965) purchased from Selleck.

    It is a viability curve of various cell lines treated the dinaciclib.

    Dinaciclib (SCH727965) purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Targets
CDK2 [1]
(Cell-free assay)
CDK5 [1]
(Cell-free assay)
CDK1 [1]
(Cell-free assay)
CDK9 [1]
(Cell-free assay)
1 nM 1 nM 3 nM 4 nM
In vitro

Dinaciclib is also a potent DNA replication inhibitor that blocks thymidine (dThd) DNA incorporation in A2780 cells with IC50 of 4 nM. Dinaciclib strongly suppresses phosphorylation of Rb on Ser 807/811 at concentrations >6.25 nM, which is in agreement with the observation that 4 nM concentrations are required for 50% inhibition of dThd DNA incorporation in the same cell model. Significantly, complete suppression of Rb phosphorylation is correlated with the onset of apoptosis, as indicated by the appearance of the p85 PARP cleavage product in cells exposed to >6.25 nM Dinaciclib. Dinaciclib is active against a broad spectrum of human tumor cell lines. [1] Addition of Dinaciclib during hydroxyurea exposure also suppresses accumulation of γ-H2AX, in a dose-dependent manner. [2] Dinaciclib inhibits melanoma cell proliferation, and drives melanoma cells into massive apoptosis. [3] Dinaciclib induces the apoptosis of several osteosarcoma cell lines including those resistant to doxorubicin and dasatinib. Dinaciclib attenuates the phosphorylation of RNAP II at serine 2 and the phosphorylation of the CDK inhibitor p27Kip1 at threonine 187. Reductions in phosphorylation activity occurrs at 12 - 40 nM Dinaciclib (4 to 16 hours post-Dinaciclib addition). Dinaciclib also reduces the phosphorylation of Rb at serine 807/811. Dinaciclib induces the apoptosis of mock- and p53-depleted U2OS cells to a similar extent. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CA46 MXjBdI9xfG:|aYOgRZN{[Xl? MYqxNFAhdk1? MVGyOEBp MXnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MVmyOVI5QTh6Nx?=
Kasumi-1 Ml\hRZBweHSxc3nzJGF{e2G7 NY\xUppNOTByIH7N Mm\tNlQhcA>? MlHubY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NX[0WI5kOjV{OEm4PFc>
U937 M3XTSGZ2dmO2aX;uJGF{e2G7 NE\wR5AzNzVxMUCgcm0> NFznOXI{KGh? MVHicI9kc3NiaX7keYN1cW:wIH;mJHhDWC1zczDhcoQh\G:5boP0doVidSC2YYLn[ZR{ NIS2XZUzPDN4MkS2OS=>
8226 MYrGeY5kfGmxbjDBd5NigQ>? NX:3So1NOi93L{GwJI5O M3vVVlQhcA>? NHPpe|hjdG:la4OgbY5lfWO2aX;uJI9nKFiEUD2xd{BidmRiZH;3cpN1emWjbTD0ZZJo\XS| NGraPYQzPDN4MkS2OS=>
H929 MXfGeY5kfGmxbjDBd5NigQ>? NGnzbmQzNzVxMUCgcm0> NGflVG81KGh? NHLQenRjdG:la4OgbY5lfWO2aX;uJI9nKFiEUD2xd{BidmRiZH;3cpN1emWjbTD0ZZJo\XS| NUe1fpNuOjR|NkK0OlU>
K562 Ml\BSpVv[3Srb36gRZN{[Xl? MXmxMlUwOy96IH7N NUn4OZV1PiCq NXzOO2lL[myxY3vzJIlv\HWldHnvckBw\iC[QmCtNZMh[W6mIHTve45{fHKnYX2geIFz\2W2cx?= M33xZVI1OzZ{NE[1
BaF3/Bcr-abl M1rvV2Z2dmO2aX;uJGF{e2G7 NY\lT3I4OS53L{OvPEBvVQ>? M3PoTFYhcA>? NFTLUldjdG:la4OgbY5lfWO2aX;uJI9nKFiEUD2xd{BidmRiZH;3cpN1emWjbTD0ZZJo\XS| NUK3PGVMOjR|NkK0OlU>
U937  M2rlWGZ2dmO2aX;uJGF{e2G7 MWiyM|ExKG6P NIOwR3I{KGh? MnTIZoxw[2u|IHnu[JVkfGmxbjDv[kBZSlBvMYOgZY5lKGSxd37zeJJm[W1idHHy[4V1ew>? M1nNcFI1OzZ{NE[1
1205Lu M4XmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHnWJUyOC9|MDDuUS=> MUm3NkBp M37DPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGGwZDDzeZJ3cX[jbB?= M{nsbFI{PTJ5MkK1
WM1366 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHQNVAwOzBibl2= M3;HZlczKGh? MoDZbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W6mIIP1dpZqfmGu MUSyN|UzPzJ{NR?=
RD M2nQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjUc2tKSzVyPUiuNkBvVQ>? MXKyNlMyPTJ2MB?=
Rh41 NHrpVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD1zMD61JI5O MnX0NlI{OTV{NEC=
Rh18 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LhcWlEPTB;MUCuOUBvVQ>? M1SyNVIzOzF3MkSw
Rh30 M4jiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn2RYtKSzVyPUmgcm0> M4PYV|IzOzF3MkSw
BT-12 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRThwNTDuUS=> M2DtXVIzOzF3MkSw
CHLA-266 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTdwMzDuUS=> NF\3XWgzOjNzNUK0NC=>
TC-71 NYeycGpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwOTDuUS=> M1jGZlIzOzF3MkSw
CHLA-9 NIfDeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TsWWlEPTB;ODDuUS=> NWXtZ5VVOjJ|MUWyOFA>
CHLA-10 M4[3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPLelZKSzVyPU[uN{BvVQ>? NX3DNpg2OjJ|MUWyOFA>
CHLA-258 NIrhZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTlwOTDuUS=> MU[yNlMyPTJ2MB?=
GBM2 NF[xfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\p[nR{UUN3ME22MlUhdk1? MWCyNlMyPTJ2MB?=
NB-1643 NFroPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnKdZllUUN3ME2zMlMhdk1? MV[yNlMyPTJ2MB?=
NB-EBc1 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTdibl2= MUKyNlMyPTJ2MB?=
CHLA-90 M3PEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX4[nBKSzVyPUeuOUBvVQ>? MlLQNlI{OTV{NEC=
CHLA-136 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\PVYhoUUN3ME25Mlghdk1? NWfXcHRlOjJ|MUWyOFA>
NALM-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfnTWM2OD12Lk[gcm0> M4jncFIzOzF3MkSw
COG-LL-317 M4nKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHiXZlFUUN3ME22MlUhdk1? M2i2PVIzOzF3MkSw
RS4;11 M2PWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVwMTDuUS=> NFW5cHYzOjNzNUK0NC=>
MOLT-4 M4W3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPNbHlpUUN3ME25MlMhdk1? MXuyNlMyPTJ2MB?=
CCRF-CEM NHjm[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPzTWM2OD13Lk[gcm0> MWiyNlMyPTJ2MB?=
Kasumi-1 NXnob5pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXMepc4UUN3ME20MlUhdk1? MX:yNlMyPTJ2MB?=
Karpas-299 NGrXfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwOTDuUS=> M3O1RVIzOzF3MkSw
Ramos-RA1 NGLPTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fveGlEPTB;Nz65JI5O NXnlc41KOjJ|MUWyOFA>
MIAPaCa-2 NYnNNWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXy3NkBp NHfSVFVIUTVyPUGwJI5O NH3ucFYzOTd4OEe3PS=>
Pa20C  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm3NkBp MXPHTVUxRTJyIH7N NEj5fVAzOTd4OEe3PS=>
ML-1 NYrQd3RZSXCxcITvd4l{KEG|c3H5 MWmxMVExODBibl2= MnK4OEBp M1LFXIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NVLvUoJ5OjF5Nki3O|c>

... Click to View More Cell Line Experimental Data

In vivo Dinaciclib i.p. administration at 8, 16, 32, and 48 mg/kg daily for 10 days results in tumor inhibition by 70%, 70%, 89%, and 96%, respectively. Dinaciclib MED (minimum effective dose) appears to be <8 mg/kg. Dinaciclib is well tolerated, and the maximum body weight loss in the highest dosage group is 5%. Dinaciclib has dose-dependent antitumor activity in vivo, and that nearly complete inhibition of tumor growth occurs at a dose level below the MTD (maximum tolerated dose). Dinaciclib has a short plasma half-life in mouse. [1]

Protocol

Kinase Assay
+ Expand

Cyclin/CDK kinase assay:

Recombinant cyclin/CDK holoenzymes are purified from Sf9 cells engineered to produce baculoviruses that express a specific cyclin or CDK. Cyclin/CDK complexes are typically diluted to a final concentration of 50 μg/mL in a kinase reaction buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 1 mM DTT, and 0.1 mM sodium orthovanadate. For each kinase reaction, 1 μg of enzyme and 20 μL of a 2-μM substrate solution (a biotinylated peptide derived from histone H1) are mixed and combined with 10 μL of diluted Dinaciclib. The reaction is started by the addition of 50 μL of 2 μM ATP and 0.1 μCi of 33P-ATP. Kinase reactions are incubated for 1 hour at room temperature and are stopped by the addition of 0.1% Triton X-100, 1 mM ATP, 5 mM EDTA, and 5 mg/mL streptavidin-coated SPA beads. SPA beads are captured using a 96-well GF/B filter plate and a Filtermate universal harvester. Beads are washed twice with 2 M NaCl and twice with 2 M NaCl containing 1% phosphoric acid. The signal is then assayed using a TopCount 96-well liquid scintillation counter.
Cell Research
+ Expand
  • Cell lines: A2780 cells
  • Concentrations: 0 μM -5 μM
  • Incubation Time: 24 hours
  • Method: A2780 cells are maintained in DMEM plus 10% fetal bovine serum and passaged twice weekly by detaching the monolayer with trypsin-EDTA. One hundred microliters of A2780 cells (5 × 103 cells) are added per well to a 96-well Cytostar-T plate and incubated for 16 hours to 24 hours at 37 °C. Dinaciclib is serially diluted in complete media plus 2% 14C-labeled dThd. Media are removed from the Cytostar T plate; 200 μL of various Dinaciclib dilutions are added in quadruplicate; and the cells are incubated for 24 hours at 37 °C. Accumulated incorporation of radiolabel is assayed using scintillation proximity and measured on a TopCounTM.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Nude mice bearing A2780 tumors
  • Formulation: 20% hydroxypropyl-β-cyclodextran
  • Dosages: 8 mg/kg, 16 mg/kg, 32 mg/kg, and 48 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 26 mg/mL (65.57 mM) warming
Ethanol 8 mg/mL warmed (20.17 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 396.49
Formula

C21H28N6O2

CAS No. 779353-01-4
Storage powder
in solvent
Synonyms PS-095760

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02684617 Recruiting rrCLL|rrMM|rrDLBCL Merck Sharp & Dohme Corp. March 2016 Phase 1
NCT01783171 Recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01711528 Suspended Recurrent Plasma Cell Myeloma National Cancer Institute (NCI) December 2012 Phase 1
NCT01650727 Completed Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma Merck Sharp & Dohme Corp. October 2012 Phase 1
NCT01624441 Active, not recruiting Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma National Cancer Institute (NCI) August 2012 Phase 1
NCT01580228 Completed Chronic Lymphocytic Leukemia (CLL) Merck Sharp & Dohme Corp. August 2012 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know how to reconstitute the inhibitor for in vivo studies?

  • Answer:

    S2768 (SCH727965) in 15% Captisol at 8 mg/ml is a suspension for oral administration. And it can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution for injection.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Dinaciclib (SCH727965) | Dinaciclib (SCH727965) supplier | purchase Dinaciclib (SCH727965) | Dinaciclib (SCH727965) cost | Dinaciclib (SCH727965) manufacturer | order Dinaciclib (SCH727965) | Dinaciclib (SCH727965) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID